SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Norris Medicines - Quaterly Results

13 Feb 2023 Evaluate
The total revenue stands at Rs. 31.64 millions for the December 2022 quarter. The mentioned figure indicates an increase of about 109.95% as against Rs. 15.07 millions during  the year-ago period.The Net Loss for the quarter ended December 2022 is Rs. -2.02 millions as compared to Net Loss of Rs. -1.87 millions of corresponding quarter ended December 2021 Operating profit Margin for the quarter ended December 2022 improved to 3.39% as compared to -0.34% of corresponding quarter ended December 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 31.64 15.07 109.95 71.45 85.99 -16.91 94.38 122.51 -22.96
Other Income 0.03 0.14 -78.57 0.03 0.30 -90.00 0.26 0.50 -48.00
PBIDT 3.39 -0.34 -1097.06 3.80 3.70 2.70 -0.46 -16.91 -97.28
Interest 3.90 4.76 -18.07 11.31 14.00 -19.21 14.82 16.34 -9.30
PBDT -0.51 -5.10 -90.00 -7.51 -10.30 -27.09 -15.28 -33.25 -54.05
Depreciation 1.51 -3.23 -146.75 4.53 0.00 0.00 6.57 6.67 -1.50
PBT -2.02 -1.87 8.02 -12.04 -10.30 16.89 -21.85 -39.92 -45.27
TAX 0.00 0.00 0.00 0.00 0.00 0.00 10.79 9.69 11.35
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 10.79 9.69 11.35
PAT -2.02 -1.87 8.02 -12.04 -10.30 16.89 -32.64 -49.61 -34.21
Equity 99.26 99.26 0.00 99.26 99.26 0.00 99.26 99.26 0.00
PBIDTM(%) 10.71 -2.26 -574.90 5.32 4.30 23.60 -0.49 -13.80 -96.47

Norris Medicines Share Price

14.25 -0.42 (-2.86%)
22-Apr-2026 14:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1666.85
Dr. Reddys Lab 1220.80
Cipla 1239.60
Zydus Lifesciences 932.80
Lupin 2310.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×